Ciphergen regains Nasdaq listing compliance

Seattle, Jan. 24 - Ciphergen Biosystems Inc. has regained compliance with the requirements for continued listing on The Nasdaq National Market, according to a company news release.

The "E" that had been added to the company's ticker symbol, "CIPH," was removed after the close of business on Tuesday.

The company first received notice of noncompliance from the Nasdaq Listing Qualifications Panel in November after it failed to file on time its 10-Q financial report for the quarter ended Sept. 30.

Ciphergen received a second notice in December, when the market value of its listed securities fell below $50 million for 10 consecutive business days.

Ciphergen Biosystems is based in Fremont, Calif., where it researches protein biomarkers and develops them into systems and services for clinical, research and process proteomics applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.